Preliminary evaluation of 5α-reductase type 2 in urine as a potential marker for prostate disease

Steroids

Volumn 62, Issue 10, 1997, Pages 682-685

  Lombardo, Michael E ^a   Hudson, Perry B ^b  

^a Bay Pines VA Medical Center   (United States)

^b NONE

Author keywords

5 reductase; Biomarker; Prostate; Urine

Indexed keywords

FLUTAMIDE; ISOENZYME; LEUPRORELIN; POLYCLONAL ANTIBODY; STEROID 5ALPHA REDUCTASE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RABBIT; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE LEVEL;

ADENOCARCINOMA; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ISOENZYMES; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030770698     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(97)00066-4     Document Type: Article

References (5)

1. Boring CC, Squires TS, and Tong T (1994). Cancer Statistics. American Cancer Society 44:22-23.
2. Lombardo ME, Meyer-Siegler K, Hakky SI, and Hudson PB (1996). Preliminary studies on the isolation and characterization of predominant prostatic proteins. Prostate 29:381-385.
3. Lombardo ME, Hudson PB (1996). Immunochemical detection of 5α-reductase in human serum. Steroids 61:651-656.
4. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulhollond SG, Gomella LG (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112.
5. Harlow E, Lane D (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.